Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

3.990 -0.140 (-3.39%)
Delayed Quote Updated: 1:01 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Postmarket Movers: After-Hours Gainers and Losers ↗
Via Chartmill
News headline image
These 3 Risky Stocks Could Be Sitting on 100% Upside ↗
Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks. 
Via MarketBeat
News headline image
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call ↗
TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate. 
Via The Motley Fool
Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗
Via Chartmill
Taysha Gene Therapies Inc (NASDAQ:TSHA) Reports Q4 2025 Revenue Beat and Key Rett Syndrome Program Updates ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
What's Next: Taysha Gene Therapies's Earnings Preview ↗
 
Via Benzinga
News headline image
Taysha Gene Therapies Q2 Earnings Call Highlights ↗
Taysha Gene Therapies (NASDAQ:TSHA) said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential... 
Via MarketBeat
Topics Earnings
News headline image
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run ↗
Nagendran Sukumar executed the sale under a pre-established Rule 10b5-1 trading plan, retaining 936,410 shares worth $5.94 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Taysha (TSHA) Q1 2026 Earnings Transcript ↗
Taysha (TSHA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline. 
Via The Motley Fool
News headline image
Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗
Taysha (TSHA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Taysha Gene Therapies Inc (NASDAQ:TSHA) Stock Slumps on Q3 Revenue Miss Despite Key Regulatory Win for TSHA-102 ↗
Taysha Gene Therapies stock fell after Q3 results, with a revenue miss overshadowing positive FDA Breakthrough Therapy designation for its Rett syndrome drug. 
Via Chartmill
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Taysha Gene Therapies Stock Falling Friday? ↗
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial. 
Via Benzinga
News headline image
Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals ↗
Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy. 
Via Stocktwits
News headline image
Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Demystifying Taysha Gene Therapies: Insights From 6 Analyst Reviews ↗
 
Via Benzinga
News headline image
Discover the most active stocks in Thursday's session. ↗
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy ↗
Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102. 
Via Stocktwits
News headline image
Which stocks are gapping on Thursday? ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Top 2 Health Care Stocks That May Keep You Up At Night This Month ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around Taysha Gene Therapies? ↗
 
Via Benzinga
News headline image
Is Taysha Gene Therapies Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.